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The Economic Costs of Cardiovascular Disease, Diabetes Mellitus and Associated Complications in 
South Asia: A Systematic Review 
 
ABSTRACT  
Background: Over 80% of global deaths caused by cardiovascular disease (CVD) and diabetes (DM) 
occur in developing countries. The burden of non-communicable disease (NCDs) in South Asia is 
increasing rapidly. 
Objectives: To estimate the costs of CVD and the costs of DM to individuals and society in 
Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka. 
Methods: We systematically searched six health and economic databases for studies identifying 
costs related to CVD or DM and their respective complications. Costs were extracted from included 
studies and converted to US$ for the price year 2015 to enable meaningful comparisons. 
Results: Of the 71 articles suitable for full text review, 29 studies met the inclusion criteria. The 
majority were cost of illness studies (n=27) and were from the patient perspective (n=23). Most 
collected data since 2000 (n=23) and included data from India (n=24). No studies included 
longitudinal costs at the patient level. Medical costs for routine management of CVD and DM were 
broadly similar. These costs escalate significantly once complications occur which require treatment, 
particularly for stroke, major coronary events and amputations. Costs are mainly borne by the 
individual and family.  Some included studies modelled rapidly rising future costs. The majority of 
studies included had methodological weaknesses.   
Conclusions: Marked increases in costs have been identified when complications of these chronic 
diseases occur, underlining the importance of secondary prevention approaches in disease 
management in South Asia.  Higher quality studies, especially those that include longitudinal costs, 
are required to establish more robust cost estimates. 
 
INTRODUCTION   
The prevalence of non-communicable diseases (NCDs) such as cardiovascular disease (CVD) and 
diabetes mellitus type 2 (DM) is increasing worldwide, especially in low and middle income 
countries(1) (LMICs). Ischaemic heart disease was the single biggest cause of disability adjusted life 
years in the global burden of disease study(2) with an estimated 31% of all worldwide deaths being 
due to CVD(3).  
The south Asia region has a population of 1.7 billion people, which has tripled since 1950. Life 
ĞǆƉĞĐƚĂŶĐǇŝŶƚŚĞƌĞŐŝŽŶŚĂƐŝŶĐƌĞĂƐĞĚĚƌĂŵĂƚŝĐĂůůǇĨƌŽŵ ? ?ŝŶ ? ? ? ?ƚŽ ? ?ǇĞĂƌƐƚŽĚĂǇ ?/ŶĚŝĂ ?Ɛ
population is by far the largest, with three-ƋƵĂƌƚĞƌƐŽĨƚŚĞƌĞŐŝŽŶ ?ƐƚŽƚĂů(4). Along with the global 
trend, the prevalence of CVD and DM in the region is expected to continue to increase in the coming 
years(5). In South Asia, some of the main drivers for this expected rise are economic transition, 
urbanisation and lifestyle changes(6). The burden of disease is shifting from infectious, maternal and 
childhood diseases to non-communicable diseases. This epidemiological transition has occurred 
rapidly and CVD, DM and their complications now contribute a significant burden of disease in these 
LMICs(7). For example, in India CVDs are now the leading cause of death in men and women in both 
rural and urban areas(1, 8). In addition, India is now the country with the second largest number of 
people living with diabetes at 65.1 million (second only to China at 98.4 million).  
According to the World Bank(9), the south Asian region has been the fastest growing economic 
region in recent years. In 2015 the combined GDP of all countries in the region was 
US$ 2,689,862million. By far the largest economy in the region is India (2015 GDP 
US$ 2,088,841million). Other economies include Pakistan (US$ 271,050million), Bangladesh 
(US$ 195,079million), Sri Lanka (US$ 82,316million), Nepal (US$ 21,195million), Afghanistan 
(US$ 19,331million), Maldives (US$ 3,435million) and Bhutan (US$ 2,058million). 
Chronic diseases have a significant health impact on individuals and their families. Analysis of NCDs 
in South Asia highlights that while the burden is currently greatest among affluent groups, many 
adverse risk factors are concentrated among the poor portending future increases amongst those 
with the least resources to manage their condition(10).  The International Diabetes Foundation (IDF) 
estimated diabetes related health care expenditure in 2014 to be approximately US$6.9 billion in the 
South Asia region(11). With limited capacity within the public health system to effectively identify 
and manage CVD and DM, healthcare costs are usually borne as out of pocket expenditure by the 
individual and their families in this region, often with catastrophic financial consequences (12-14).  
Although some countries in the region are beginning to explore social insurance schemes to fund 
healthcare expenditure, there is limited existing evidence to inform policy makers of these costs(15). 
A few literature reviews have been conducted, exploring some relevant aspects of this issue. 
ƌŽƵǁĞƌĞƚĂů ? ?ƐƌĞǀŝĞǁŽĨƉƌŽǀŝĚĞƌĐŽƐƚƐƌĞůĂƚĞĚƚŽsŝŶ>D/Ɛ(16) found a wide variation in costs 
but little evidence from low income countries. YesudiĂŶĞƚĂů ? ?ƐƌĞǀŝĞǁ(17) of the costs of DM in India 
found medication to be a large proportion of costs with the burden falling heaviest on the poor and 
ƵƌďĂŶƉŽƉƵůĂƚŝŽŶƐ ?^ĞƵƌŝŶŐĞƚĂů ? ?ƐƌĞǀŝĞǁ(18) of the economic costs of DM in relation to levels of 
national GDP found direct costs to be generally higher than indirect costs, with these direct costs 
ďĞŝŶŐƉŽƐŝƚŝǀĞůǇĂƐƐŽĐŝĂƚĞĚǁŝƚŚĂĐŽƵŶƚƌǇ ?Ɛ'WƉĞƌĐĂƉŝƚĂ ?EŽŶĞŽĨƚŚĞƐĞƐƚƵĚŝĞƐĂĚĞƋƵĂƚĞůǇ
addressed the question of all relevant economic costs, focused specifically on the South Asian 
region.  
The aim of this systematic review, was to estimate the costs of CVD and the costs of diabetes to 
individuals and society, in the LMICs of the South Asia region according to the World Bank 
definition(19) which includes Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and 
Sri Lanka. This review sought to identify and collate data from peer-reviewed studies to address the 
question: What are the economic costs related to cardiovascular disease and the economic costs 
related to diabetes mellitus and their complications on society, the health sector, individuals and 
their families in South Asia? 
  
METHODS   
This review was undertaken according to the Centre for Reviews and Dissemination guidelines for 
systematic reviews and meta-analyses(20). A protocol was developed to plan the review which is 
available from the authors on request. The review is reported according to PRISMA guidelines(21).  
Search Strategy 
In April 2015 we searched the databases listed below for studies containing costs of CVD and DM in 
the countries of South Asia: 
 ? EconPapers (RePec) 
 ? Embase Classic Embase (Ovid) 1947 to 2015 April 01 
 ? Global Health (Ovid) 1973 to 2015 Week 12 
 ? Ovid MEDLINE(R) 1946 to March Week 5 2015 
 ? Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations April 01, 2015 
 ? NHS Economic Evaluation Database : Issue 1 of 4, January 2015 (Wiley) 
 ? WHOLIS  World Health Organization Library & Information Networks for Knowledge 
Database 
 
The search strategy comprised subject headings and text words identified by the project team and 
known relevant papers for the search concepts CVD, DM, Costs and South Asia. The CVD search 
concept was adapted from a Cochrane CVD review(22). Table 1 illustrates some of the terms we 
used, however the full search strategy can be found in the appendices. The results of the electronic 
searches were stored and managed in an EndNote library. Relevant references, cited in the 
identified studies, were also included, as well as any relevant studies that the authors already had 
from previous work. We did not have the financial and human resources to contact study authors.
  
Insert Table 1 here  
 
Inclusion criteria 
Studies were considered as eligible for inclusion, if they related to the specified countries in the 
World Bank South Asia region and if they related to any aspects ŽĨ “ĐŽƐƚ ?ŝŶƌĞůĂƚŝŽŶƚŽsŽƌ DM. 
Our aim was to obtain to the fullest extent possible, relevant costs related to CVD, DM and their 
complications. We used a broad definition of cost including all perspectives and elements of costs or 
economic impacts. Therefore, we included costs related to CVD or costs related to DM as incurred by 
service users and their families, service providers, governmental organisations and society. We 
included any types of costs regardless of any categorisation made by authors including: direct, 
indirect and/or intangible costs. Inclusion of studies was not restricted by specific participants or 
settings with the aim of capturing all relevant costs of CVD, relevant costs of DM and the 
complications of either disease. Study designs included in the review were randomised controlled 
trials (RCTs); observational studies; cost-of illness studies and systematic reviews.   
We included all participants diagnosed with either DM or CVD (including ischaemic heart disease, 
stroke, hypertension and congestive heart failure) and their complications. We also included studies 
that included patients with co-morbid CVD and DM. In regard to costs of diabetes, our study aims 
were focused on type 2 DM. However, studies not clearly specifying which type of DM or combining 
results for both type 1 and 2 were included. We did not include studies exclusively looking at type 1 
or gestational diabetes mellitus.  
 
Exclusion criteria 
We excluded studies if there was no full text publication available; if it was a conference abstract; if 
it was written in a language other than English, Hindi, Urdu or Bengali; and, if it included costs that 
did not relate to usual care in that setting at the time (e.g. only related to costs of a novel 
intervention). Cost-benefit, cost-effectiveness, cost-minimisation and cost-utility analyses were not 
completely excluded but reviewed separately to identify possible sources of cost data. Systematic 
reviews were included to ensure that any relevant studies included in other reviews were also 
identified in ours. The systematic review itself was not included in our analysis as this would have led 
to double counting of data.  
 
Study Selection 
Following implementation of these search strategies, the title and abstract of each identified study 
were reviewed by one author and the inclusion/exclusion criteria applied. The full text articles of the 
short-listed studies were then reviewed independently by two authors using an extraction form and 
quality checklist. The two sets of quality scores were then reviewed by both authors together and 
discrepancies discussed to agree a consensus score for each study.  If the two reviewers were unable 
to reach consensus on the scoring, a third reviewer was asked to assess the relevant points in the 
study and adjudicate.  
 
Data Extraction, Quality Scoring and Risk of Bias 
We developed a data extraction tool and two of the study team (FG and HE) tested it on 5 studies 
before it was used to extract the relevant data from the reviewed studies. The tool can be found in 
the appendices. Only information available in the publication was used for assessing inclusion 
criteria, for data extraction, and for quality assessment. 
A number of different quality checklists are available in relation to economic evaluation but there is 
currently no universally accepted checklist that was suitable for this review. Therefore we developed 
a quality assessment checklist for this study, based on a review of a number of existing checklists(20, 
23-30).  This checklist enabled an assessment of risk of bias to be undertaken using a scoring system 
across 38 quality criteria. These criteria covered a full description of; methods, context and 
economic study design; quantification of resources and costs; currency, price year and discounting; 
uncertainty and sensitivity analysis; and appropriate reporting of results and conclusion. We scored 
the ƐƚƵĚŝĞƐǁŝƚŚ ?ƉŽŝŶƚĨŽƌ ‘ǇĞƐ ? ? ? ? ?ĨŽƌ ‘ƉĂƌƚŝĂů ?Žƌ ‘ƵŶĐůĞĂƌ ?ĂŶĚ ?ĨŽƌ ‘ŶŽ ?Žƌ ‘E ?ĨŽƌĞĂĐŚŽĨƚhese 
criteria. The total score is presented as a percentage of the available scores for each study, thus we 
did not score studies down for non-applicable ratings. This assumes that each criterion carries equal 
weight in the overall score. We did not exclude studies for a poor quality score, however the score is 
presented in table 3 and should be considered in the interpretation of results. 
 
Summary Measures 
The vast majority of studies included in this review are cost of illness studies. We reported our 
findings in standard health economics terms(30): medical direct costs (financial transactions for 
health services), non-medical costs (financial transactions for non-medical services e.g. transport), 
indirect costs (lost productivity) and intangible costs (disvalue to an individual such as pain or 
suffering). Most units of measurement are reported as mean annual cost per patient or mean annual 
cost per hospital admission. Once we extracted these costs from each included study, we converted 
them to US$ for the price year 2015 (using Purchasing Power Parity data from the IMF), in order to 
enable meaningful comparisons. This was done using an online cost converter (v1.5 accessed in May 
2016) designed for this purpose and found at http://eppi.ioe.ac.uk/costconversion/ (31). We 
grouped our findings by disease and by the presence of complications to assist with further 
comparison. Where studies collected data over several years and had not been adjusted to one price 
year, we took the mid-year as the original price year for conversion. 
As studies included in this review reported findings for different diseases, with a range of 
complications in a variety of settings, it was not possible for us to synthesise the data into a meta-
analysis. The findings of this systematic review are therefore descriptive in nature.  
 
Results  
We identified 1,437 articles from our searches (after duplicates had been removed). Five of these 
came from reference lists of other systematic reviews. Of these, 1,366 were excluded after screening 
titles and abstracts as not meeting our inclusion criteria. Of the remaining 71 articles that were 
eligible for full text review, 42 were excluded (the reasons are listed in Fig. 1) which left 29 studies to 
be included in our review. 
Insert Fig. 1 here  
  
Study Characteristics (see Table 2) 
The vast majority of the studies (n=27) were cost of illness studies. The two remaining studies were 
economic modelling studies(32, 33). Most studies assessed costs from the patient perspective (n=24) 
with the rest being from the societal perspective (n=5). An important gap in the evidence base is the 
lack of information from half of the countries, with only 4 out of the 8 South Asia countries 
contributing to included studies. The results will, to a degree, be Indo-centric as the majority of 
studies (n=23) provided data from India. The other three countries represented were Pakistan (n= 5), 
Bangladesh (n=1) and Nepal (n=1). Most studies were set in public or private hospitals (n=22; of 
which 8 were across multiple sites and 4 were outpatient departments only). Other settings included 
a district/region (n=3) and nationwide settings (n=4). Most studies were quite recent, only six studies 
had collected data before the year 2000. 
Sample sizes within the cost of illness studies ranged from 150 to 383,000 individuals, with a median 
sample size of 400. Twenty studies included data for DM (type 2 (n=7) or not stated (n=13); with 11 
of these DM studies including complications of the disease). Eleven studies included data for CVD, of 
which, some included participants with DM (n=2) and some related specifically to stroke (n=3), 
hypertension (n=2) and angina (n=1). Of the 23 studies that reported mean age of the sample, the 
range of means was 49 to 70 years old. Of the 24 studies that reported on the sex ratio of the 
sample, males were in the majority in 20 studies (% males pooled across 24 studies = 56%). 
Sources of cost data were obtained from self-reporting (n=21), hospital records (n=9), national 
reference costs (n=5) and international reference costs (n=2) with some studies combining several 
sources. As the majority were cost of illness studies it is unsurprising that the vast majority of 
included studies reported direct medical costs (n=28). These were mainly costs for consultation fees, 
medicines, lab investigations, admission charges, bed fees, surgery costs, nursing charges and 
rehabilitation fees. A lesser proportion of studies included direct non-medical costs (n= 17) which 
were mostly transport and food costs. Fewer studies still included indirect costs (n=5) which were all 
estimates of loss of productivity. One study included intangible costs which estimated a willingness 
to pay value using a bidding method. The currencies that studies reported in were Indian rupees 
(n=20), US dollars (n=7), Pakistan Rupees (n=4), International dollars (n=2) and pounds sterling (n=1). 
Seven studies were authored by researchers from the same WHO Collaborating Centre for Research 
in Chennai, India(34-40) and three studies were from a study group in Bangalore(41-43). The results 
from our quality checklist indicate that many studies failed to report substantial elements of their 
methods, therefore, poor internal validity is a risk for these studies. 
Insert Table 2 here  
 
Risk of Bias within studies (see Table 2) 
Using our quality checklist, we identified scores for included studies that ranged between 40.9% and 
89.1%. The median score was 71.0%. The distribution of scores for the 29 studies is represented in 
Fig. 2. Seven studies had a quality score below 60%. Five studies had a quality score exceeding 80%. 
There were no obviously similar study characteristics between poorly scoring studies. There was a 
similar range of quality scores for studies that included participants with DM compared to studies for 
CVD. The studies with low quality scores were spread across all diseases and study types (see table 
3). 
Insert Figure 2 here 
 
Annual economic costs of CVD per person (see Table 3) 
There were eleven studies that estimated economic costs for CVD in some of the countries of South 
Asia. One study from India(44) estimated the annual direct medical cost of managing hypertension 
on an outpatient basis as US$ 386. Another study from India(45) estimated the annual cost of all 
CVD care as US$ 563. When patients are admitted to hospital with CVD significant costs are incurred 
with a range of US$ 677 - 1,523(33, 46, 47) per hospitalisation. Among the studies that estimated 
hospitalisation costs for CVD, the earlier studies tended to have lower costs than later studies (even 
after adjusting for price year). For the routine management of CVD, drug costs were estimated in 
four studies(44, 46, 48, 49). For the management of hypertension the range of annual drug costs was 
US$ 79 - 231(44, 46, 48) and for CVD (defined broadly) the drug costs were estimated to be US$ 1.14 
per day, or US$ 415 per year(49).  
Given that stroke care requires significant treatment and rehabilitation as an in-patient and that all 
three studies that captured costs for stroke care (Pakistan=1, India=2) sampled in-patients, it is not 
surprising that estimates of costs were some of the highest found in this review. The range of direct 
medical costs associated with each stroke(50-52) was US$ 3,890 - 28,451, with the range of direct 
non-medical costs being US$ 357 - 1,552. Along with direct costs, indirect costs for transport and 
home adaptations for stroke were also substantial; estimated at US$ 872  W 1,719 per 
hospitalisation(51, 52). Overall costs of each stroke from a societal perspective were estimated(51, 
52) to be US$ 5,966 - 32,927. Given that the included studies only captured post-stroke data for 6 or 
12 months, the longer term cost to society is likely to be substantially more (particularly indirect 
costs).  
From a societal perspective the direct and indirect costs of CVD are considerable. Direct medical 
costs for CVD were estimated(33) to be US$ 10.2 billion for India in 2004. This data was then 
projected for the years 2016 and 2021 as US$ 14.4 billion and US$ 16.6 billion respectively which 
suggests a significant rise, in line with the growth in both population and prevalence. The authors 
emphasise that this impact falls predominantly on the working age population. Another study(32) 
modelled the estimated indirect costs of loss of productivity to the economies of India, Pakistan and 
Bangladesh, from CVD in 2015, which were estimated to be US$ 1.96 billion, US$ 0.21 billion and 
US$ 0.14 billion respectively.  
 
Annual economic costs of DM per person (see Table 3) 
There were eighteen studies that estimated costs for DM in some of the countries of South Asia. 
Estimated costs for DM differed in terms of the type of costs that were included. Where costs were 
limited to outpatient care(41-43, 53-55) a range of US$ 463 - 951 was found for mean direct medical 
costs. In studies that disaggregated these totals further for sub-samples within their data, the range 
of costs increased. For instance one study(55) in India reported that patients that used a 
Government funded outpatient service (compared to a private outpatient service) had lower costs at 
US$ 212 and a different study(35) identified mean direct costs of US$ 1,046 for urban patients and 
US$ 655 for rural patients. When hospital admissions were included in direct medical costs the range 
of mean direct medical costs rose slightly to US$ 575 - 1216(37, 43, 53, 56). However the largest 
direct medical costs reported by studies(40, 57, 58) were for DM patients with complications, which 
had a range of US$ 246  W 4,597. The studies(57, 58) reported that complications with lower costs 
(US$ 246  W 502) were nephropathy and peripheral vascular complications such as minor foot ulcers. 
Higher costs (US$ 2,087  W 4,597) related to severe foot ulcers, amputations and coronary events. 
Similar patterns to direct medical costs were seen for direct non-medical costs; with lowest costs for 
DM patients seen in outpatients only(54, 55) (range US$ 12  W 21) with higher costs for those who 
were also admitted to hospital(53) (US$ 258) and a greater range for those with complications(34, 
36, 39, 40) (cost per admission range US$ 50  W 470). A wide range of mean annual indirect costs 
were estimated by studies(39, 41, 43, 53-55) for DM and its complications which ranged from US$ 9 
up to US$ 2,803. 
One study(39) estimated intangible costs for DM, as a willingness to pay, using a bidding method. 
This study found that on average patients were willing to pay US$1,936 a year to stay well. However, 
there was a significant range when broken down by number of complications (US$ 1,452 for no 
complications to US$ 7,260 for >4 complications) and by HbA1c level (US$ 484 for HbA1c <7 to 
US$ 1,936 for HbA1c >9). 
When combining costs to obtain an overall estimate, costs similarly varied. A number of studies(34, 
36, 40) modelled 2 year expenditure estimates based on their data for total direct costs (medical and 
non-medical) which included data for serious complications of DM. The range of these 2 year costs 
were US$ 2,420 to US$ 40,331 (or annual costs of US$ 1,210  W 20,166). Estimates from studies that 
additionally included indirect costs (to direct costs) tended to have much lower estimates as they 
were outpatient only or mixed outpatient and inpatient samples with fewer complications and so 
attracted lower costs. The range of total annual (direct and indirect) costs for these studies(41, 43, 
54, 55, 59) was US$ 483  W 2,637. The study(39) that estimated costs incorporating direct, indirect 
and intangible costs estimated annual total costs of US$ 2,048.  
  
Insert table 3 here 
 
 
Discussion  
Our review found broadly similar estimates of annual direct medical costs per person in South Asia 
for routine management of CVD compared with routine management of DM, with costs of US$ 386 
for hypertension, US$ 563 for CVD and US$ 463  W 951 for DM outpatient care and US$ 575  W 1216 
for all DM care. Importantly, when complications (such as stroke, severe foot ulcers, amputations 
and coronary events) of these diseases occurred and required treatment, there was a substantial 
increase in costs. For severe complications of DM the direct medical costs rose to US$ 2,087  W 4,597. 
For the occurrence of each stroke, direct medical costs were estimated to be US$ 3,890 - 28,451. 
These findings indicate that the financial burden of treating the complications of CVD and DM in 
South Asia form a significant proportion of the overall financial burden of these diseases. Total 
annual direct costs for CVD in India have been modelled at US$14.4 billion in 2016, which is set to 
increase to US$16.6 billion by 2020. An economic imperative therefore clearly exists for policy 
makers in South Asia to increase preventative approaches, both to decrease the incidence of DM 
and CVD and to increase early detection as well as provide access to evidence based treatments in 
order to reduce the prevalence of costly complications. 
The economic burden of these considerable direct costs borne by the patient as out-of-pocket 
expenditure (and increasingly by social insurance schemes) in the region is compounded by the 
indirect costs to individuals and families. Our review has identified total annual costs (direct and 
indirect) of US$ 1,210  W 20,166 per person for DM and US$ 5,966  W 32,927 for each patient suffering 
a stroke. At the national level an estimate of total economic burden of DM in India was US$ 99.2 
billion to US$148.2 billion. This economic burden at the societal level is set to grow considerably 
across South Asia as the rapid epidemiological transition is set to continue. The recent increases in 
rates of smoking amongst the young, sedentary lifestyles and the consumption of added sugars and 
processed carbohydrates are projected to continue, increasing the prevalence of CVD and DM(62, 
63). The ability of countries in the region to address this rising burden will depend on their 
commitment to preventative economic and health policies such as taxation, education, food 
labelling and health promotion in schools(64, 65). 
 
Insert Table 4 here 
 
The quality checklist that we developed for this study provided a wide range of quality scores for the 
included studies in our review. Studies with higher quality scores (>70%) tended to be those using 
more sophisticated research methods such as macro-economic modelling, multi-country data 
collection or estimation of indirect or intangible costs. Conversely, cost of illness studies had a wide 
range of quality scores with some scoring very poorly.  The findings from our quality checklist 
support the criticism of cost of illness studies, concerning their variable results and lack of reliability 
due to the heterogeneity of methods employed(66). In order to improve the value of cost of illness 
studies, researchers should ensure they employ a robust methodological approach and follow 
recognised reporting standards (such as the CHEERS statement(28)). The main limitations of studies 
were: the inadequate description of the study population and therefore uncertainty about their 
representativeness; a lack of categorisation into commonly used economic categories (direct 
medical, direct non-medical, indirect and intangible costs); the unit costs and the sources of cost 
data were often not stated; the quantity of resource utilisation was not usually reported separately 
to the cost data; the perspective taken for the study was not often specified; and there was a lack of 
clarity about who bore the payment for costs identified.  
The time horizon for most studies was a single year. No studies presented longitudinal costs. Given 
the chronicity of CVD and DM this is an important consideration. As life expectancy increases across 
South Asia(19) patients can expect to live longer with these diseases with increasing risks of 
developing associated complications and therefore an escalation of related health care costs. It is 
unclear how accurate these annual estimates are for cumulative costs for patients and society over 
ƚŚĞŝŶĚŝǀŝĚƵĂů ?ƐůŝĨĞ ?^ƚƵĚŝĞƐƚŚĂƚĐĂůĐƵůĂƚĞĐŽƐƚƐŽĨsĂŶĚDŽǀĞƌƚŚĞŵĞĚŝƵŵƚŽůŽŶŐƚĞƌŵŝŶ
South Asia would be welcomed. 
Limitations 
There are several limitations to our review. Firstly, the results are dominated by studies from India. 
No studies provided data for Sri Lanka, Maldives, Afghanistan and Bhutan so the findings cannot 
easily be generalised to the region as a whole. Secondly, we only reviewed published literature and 
therefore some relevant data in grey literature (including non-indexed regional journals) may have 
been missed, limiting the comprehensiveness of our review. Thirdly, we did not contact authors to 
obtain clarifying information, which may have enriched the included data and subsequent findings. 
Lastly, we did not exclude studies from our review based on a low quality score from our checklist, 
so the internal validity of some studies is questionable. However, we have presented the quality 
scores to allow readers to interpret results accordingly. We recognise the limitations of using a 
checklist scoring system to assess risk of bias and the fact that all criteria carried equal weight. 
Further research to explore weighting these criteria and to validate the scoring system could 
improve this tool.  
 
Conclusion 
This systematic review of the economic costs of CVD, DM and their associated complications in 
South Asia has identified significant costs to individuals and families who bear the brunt of this 
financial burden currently. Marked increases in costs have been identified when complications of 
these chronic diseases occur, underlining the importance of secondary prevention approaches in 
chronic disease management.  This review has summarised the current available evidence. However, 
given the variable quality of cost of illness studies included, the findings of this review are tentative. 
Higher quality studies from every country across the region, especially those that include 
longitudinal costs, are required to establish more robust cost estimates.  
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Figure 1 - Flow Diagram of the Study Selection Process 
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Table 1 ʹ Example search terms used in the search strategy 
Concept Subject Headings Text words 
Diabetes 
Mellitus 
Diabetes Mellitus/ Diabet*, niddm, mody 
CVD Cardiovascular Diseases/ Heart 
Diseases/ Hypertension/ 
Vascular diseas*, cardiovascular diseas*, 
stroke, thrombosis, heart attack* 
South Asia /ŶĚŝĂ ?WĂŬŝƐƚĂŶ ?ĂŶŐůĂĚĞƐŚ ?ĞƚĐ ? Indian, India, Pakistan*, Nepal*, 
Afghanistan* 
Cost Costs and Cost Analysis/ 
Budgets/ 
Cost* of illness, economic* burden, 
medical expenditure*, economic 
evaluation* 
  
Table 2. Characteristics of included studies 
Ref. Country Setting Sample 
size 
Sample 
Characteristi
cs 
Year of 
data 
collecti
on 
Conditi
on 
Include
s 
complic
ations 
Economic 
Study 
Type & 
Perspecti
ve 
Study type Sources of cost data 
Cost Types & 
Descriptions 
Currency 
Reported 
Abegu
nde 
2007(3
2) 
Pakistan
, India, 
Banglad
esh 
National 
Not 
applicabl
e 
Not applicable  1950-2002  
CVD 
(Heart 
disease 
& 
stroke) 
and DM 
Yes 
Economic 
growth 
models; 
societal 
Multi-country 
comparative 
analysis 
Death registers,  
MoH surveillance, 
World Bank 
estimates, WHO 
disease scenarios. 
Effect of premature 
deaths from chronic 
diseases on the 
FRXQWULHV¶QDWLRQDO
income, which is 
measured in gross 
domestic product 
(GDP) losses per 
working-age 
population. 
US$ 
Adiga 
2010(6
0) 
India 
(Karnata
ka) 
Specialt
y 
Hospital 
238 
patients 
3 groups - 
mean age 
57.8 - 65.5 
yrs, male 43 - 
57% 
2008 DM type 2  Yes 
Cost of 
illness; 
patient 
cross-
sectional 
case note 
review study 
Hospital medical 
records department 
Direct Medical cost: 
medicine, 
consultations, lab, bed 
charge, surgery, total 
annual cost during 
hospitalisation 
Indian 
Rupees 
(INR)  
Akari 
2013(5
9) 
India 
(Andhra 
Pradesh
) 
Specialit
y 
hospital, 
150 
patients 
Male 67%, 
24% illiterate 2012 DM Yes 
Cost of 
illness; 
patient 
Case note 
reviews and 
interviews 
Patient's notes; 
self-reporting; 
interviewing health-
care professionals.  
Direct medical costs: 
medication, lab, 
consultation, 
hospitalization,  
Direct non-medical: 
travel, food 
Indirect costs: 
productivity loss  
INR/US$ 
Ali 
2008(5
7) 
Pakistan 
Specialt
y 
Hospital 
214 
64% male, 
mean age 
52.7 years 
1997- 
2004 
DM (foot 
ulcers) 
Yes 
Diabetic 
foot 
ulcer 
Cost of 
illness; 
patient 
Retrospectiv
e case note 
review 
Hospital charges 
Direct medical costs: 
OP consultation, 
investigations, 
medicines, 
hospitalization, 
surgery, home visits, 
plaster casts 
Pakistan 
Rupees & 
£  
Chand
ra 
2014(5
3) 
India 
(Pune) 
Specialt
y Clinic 
219 
patients 
Male 58.1%, 
Mean age 
54.9 years 
2011-12 DM 
Yes 
(ophthal
mology 
clinic) 
Cost of 
illness; 
patient 
Questionnair
e survey and 
interviews 
Self-reporting 
Direct medical costs: 
PHGLFLQHVGRFWRU¶V
fees, investigations, 
spectacle, laser 
treatment, surgery   
Direct non-medical 
costs: travel, food, 
dietary advice  
Indian 
Rupees 
Indirect costs: 
productivity loss 
Clarke 
2010(5
8) 
India  
215 
clinical 
centres 
in 20 
countrie
s 
471 
Over 55 yr old 
with mean age 
65.1 yrs, male 
53% 
2001-6 DM 
yes 
(macrov
ascular) 
Cost of 
illness; 
patient 
Multi-country 
comparative 
analysis 
WHO CHOICE 
economic model for 
bed day unit costs 
Unit inpatient bed day 
cost per country 
Internation
al $  
Hussai
n 
2014(6
1) 
Pakistan 
(Karachi
) 
15 
different 
outpatie
nt clinics 
at 5 
sites 
885 
patients 
male 46.2%, 
graduate or 
higher 46%  
not 
mention
ed 
DM type 
2  
not 
specified 
Cost of 
illness; 
patient 
Patient 
questionnair
e survey 
Self-reporting 
Direct medical costs : 
consultations, lab tests, 
home testing, medicine 
& syringes  
Direct non-medical: 
travel, food 
Pakistani 
Rupees  
Jhaj 
2001(4
8) 
India 
(Chandi
garh) 
Outpatie
nt 
departm
ent 
(OPD) of 
Govern
ment 
Hospital 
300 
prescript
ions  
(173 
patients)  
male 51%; 
mean age 
53.4 (men) 
and 51.8 years 
(women). 
06/1999-
11/1999 
Hyperte
nsion 
yes, not 
specific 
Cost of 
illness; 
patient 
Prescription 
review 
Current Index of 
Medical Specialities 
(CIMS) 1999, 
Indian 
Pharmaceutical 
Guide 1999 
Only including costs of 
prescriptions/ drugs for 
patients with 
hypertension 
Indian 
Rupees 
(INR)  
Kapur 
2007(4
1) 
India 
187 
towns 
across 
India 
5516 
patients 
mean age 
53.7 (for DM 
type 2: 55.2 
years) 
1999 DM 
Yes - 
not 
specific 
Cost of 
illness; 
patient 
Patient 
questionnair
e survey 
Self-report & 
responses of 
clinicians 
Direct medical costs: 
est. total monthly 
expenditure on 
investigations, OP 
clinic, medicines, lab 
tests  
Direct non-medical 
costs: travel & misc. 
costs 
Indian 
Rupee 
(INR) 
Karan 
2014(4
5) 
India 
(national
) 
commun
ity ( 
househo
ld 
survey ) 
in India 
74 000 
househo
lds, 383 
000 
individua
ls  
45% rural, 
male 50% 2004 CVD 
Yes - 
CVD 
Cost of 
illness; 
patient 
National 
household 
survey 
Self-reporting (from 
national household 
survey, India) 
Direct medical costs: 
hospital care, 
outpatient,, drugs  
Direct non-medical 
costs: travel 
Internation
al Dollar 
(INTS$)  
Kheala
ni 
2003(5
0) 
Pakistan 
Specialt
y 
hospital 
443 
mean age 58 
years, Male 
61% 
1998-
2001 
CVD 
(acute 
stroke) 
Yes -
stroke 
Cost of 
illness; 
patient 
Case note 
review 
Medical billing 
records 
Direct medical costs:  
hospitalization, drug, 
diagnosis 
Pakistan 
Rs / US$ 
Khowa
ja 
2007(5
4) 
Pakistan 
(Karachi
) 
6 
outpatie
nt clinics 
in 3 
different 
sites. 
(public, 
private 
and 
NGO)  
345 
Male 36.5%, 
38% aged 51-
60yrs, 36% 
aged 41-
50yrs, 26% 
aged 20-40yrs 
2006 DM not 
specified 
Cost of 
illness; 
patient 
Patient 
questionnair
e survey 
Self-reported, The 
Pharmacy guide 
2004, National 
Health Survey 
Pakistan (NHSP), 
Govt. of Pakistan 
Direct medical costs: 
medicines, OP 
consultation, lab tests 
Direct non-medical 
costs: travel and food 
Indirect costs: loss of 
productivity 
Pakistani 
Rupees  
Kumar 
2008(4
2) 
India 
(Delhi) 
High 
income 
wards of 
Delhi 
819 
subjects 
from 
20,666 
househo
lds 
Male 51%, 
Mean age 54 
years 
09/2005-
12/2005 
DM type 
2  No 
Cost of 
illness, 
patient 
perspectiv
e 
Household, 
cross-
sectional 
survey 
Self-reported 
Direct medical costs - 
medicine use, lab tests, 
glucose testing and 
consultations. 
Indian 
Rupees 
(INR)  
Kumpa
tla 
2013(3
4) 
India 
(Chenna
i) 
Hospitali
sed pts 
in a 
Tertiary 
Hospital 
- 
Speciali
zed 
diabetes 
care 
centre  
368 
(Stratifie
d into 6 
groups 
dependi
ng on 
complica
tions) 
Mean age 58 
years, 70% 
urban 
06/2008-
12/2009 
DM type 
2 with 
complica
tions 
Yes 
Cost of 
illness, 
patient 
perspectiv
e 
cross-
sectional 
patient 
questionnair
e survey 
Self-reported and 
hospital bills 
Direct medical costs - 
current admission 
(medical consultations, 
lab, 
medicines, admission, 
surgery, investigations) 
and previous 2 years 
expenditure 
Direct non-medical 
costs - carer costs,  
transportation,  
Indian 
Rupee 
(INR) 
Kwatra 
2013(5
1) 
India 
(Punjab) 
Stroke 
Unit and 
Neurolo
gy clinic 
of a 
tertiary 
referral 
centre 
189 
Mean age 58 
years, male 
68% 
04/2009-
10/2011 
Stroke 
(CVD) No 
Cost of 
illness, 
societal 
perspectiv
e 
Patient 
questionnair
e survey, 
medical 
records 
review 
Hospital bills, self-
reported 
Direct medical costs - 
admission, lab, 
radiology, 
investigations, drugs, 
nursing, appts, rehab 
Direct non-medical 
costs - 
travel, relocation, food, 
lodgings, changes to 
house etc. 
Indirect costs - 
productivity losses 
Indian 
Rupees ( 
INR) 
Malhot
ra 
2000(4
6) 
India 
(Chandi
garh) 
Tertiary 
public 
sector 
hospital 
336 
Mean age 62 
years, male 
68% 
6 month 
period in 
1999 
Unstable 
angina 
(CVD),  
No 
Cost of 
illness, 
patient 
perspectiv
e 
Case note 
review & 
patient 
interviews 
Pharmacy price list 
and self-reporting 
Direct medical costs -  
(single admission) 
admission, 
prescription, coronary 
care unit, ward, 
interventions, 
investigations 
US$  and 
INR  
Malhot
ra 
2001(4
4) 
India 
(Chandi
garh) 
Tertiary 
hospital 
outpatie
nt 
departm
ent 
1,076 
Male 56%, 
mean age 
male: 51 yrs, 
female: 53 yrs 
January-
Decemb
er 2000 
Hyperte
nsion 
(CVD) 
no 
Cost of 
illness 
study, 
patient 
perspectiv
e 
Medical 
records 
review and 
patient 
interview 
Self-reported, 
hospital billing, 
pharmacy price list 
Direct medical costs -  
Lab investigations, 
Drugs, Physician fees, 
ADRs (adverse drug 
reactions) 
US$ 
(Indian 
Rupees)  
Marfati
a 
2014(5
2) 
India 
(Mumbai 
& 
Bangalo
re) 
Tertiary 
Hospital
s 
400 
Mean age 61 
years, Male 
62% 
Jan 
2010-
Dec 
2011 
Stroke , 
with 
non-
valvular 
atrial 
fibrillatio
n 
no 
Cost of 
illness, 
societal 
Patient 
questionnair
e survey and 
case note 
review 
Hospital billing 
records 
Direct Medical Costs - 
Inpatient 
(hospitalisation, 
surgery, imaging, lab, 
medicines, rehab, 
ambulance) Outpatient 
(consultations, 
imaging, lab, 
medicines, rehab, 
nursing) 
Direct non-medical 
costs - Home 
modifications, transport 
Indirect costs -  lost 
productivity 
INR and 
US$ 
Ramac
handra
n 
2007(3
5) 
India 
Various 
hospitals
, clinics 
and rural 
areas of 
7 states 
in India 
556 
56% urban, 
male 61%, 
mean age 56 
years (urban) 
and 55 years 
(rural) 
2005 (1 
month) 
DM type 
2  no 
Cost of 
illness, 
patient 
perspectiv
e 
Patient 
questionnair
e survey 
Self-reported 
Direct medical costs - 
medicines, lab, 
investigations, 
consultations, 
hospitalization, surgery 
Indian 
Rupees ( 
INR) 
Rao 
2011(4
7) 
India 
(national
) 
Nationwi
de India 
(all 35 
states) 
Diabetes 
- 438 
inpatient
s 
For CVD 
- 2,129 
inpatient
s 
CVD group - 
mean age 52 
years, Male 
54% 
DM group - 
mean age 55 
years, Male 
51% 
01/2004-
06/2004 
CVD 
and 
diabetes 
mellitus 
no 
Cost of 
illness; 
patient 
perspectiv
e 
Cross 
sectional 
household 
survey 
Self-reported 
Direct medical costs - 
doctors, medicines, 
lab, bed fee, nursing, 
physio, appliances, 
other (food, blood, 
oxygen, ambulance) 
Direct non-medical 
costs - transport, food 
and lodgings 
Indian 
Rupee 
(INR) 
Rayap
pa 
1999(4
3) 
India 
(Bangal
ore) 
Various 
- 
hospitals 
and 
primary 
and 
commun
ity 
health 
centres 
(public 
611 Male 55%, illiterate 21% 1997 DM no 
Cost of 
illness, 
patient 
perspectiv
e 
Patient 
questionnair
e survey 
Self-reported 
Direct medical costs - 
Weekly expenditure on 
care, tests undertaken, 
hospitalisations 
Indirect costs - Working 
days lost and loss of 
personal/family income 
Indian 
Rupees 
and 
private) 
Satyav
ani 
2014(3
6) 
India 
 a 
specializ
ed 
diabetes 
care 
centre 
and a 
private 
hospital 
209 
(split 
into 4 
groups 
dependi
ng on 
status of 
CKD) 
Mean age 64 
yrs. Male 58%, 
60%, 76% and 
57% in 4 
groups 
Aug 
2008 - 
Jan 
2010 
DM type 
2 with or 
without 
CKD 
Yes only 
CKD 
Cost of 
illness, 
patient 
perspectiv
e 
Patient 
questionnair
e survey and 
medical 
billing review 
Self-reported and 
hospital bills 
Direct medical costs - 
first admission (lab & 
consultations), 
medicines (monthly) 
and per hospitalization 
(surgery, bed fee, 
nursing), dialysis, total 
expenditure in past two 
years 
Direct non-medical 
costs - travel 
Indian 
Rupees 
(INR)  
Shastr
y 
2015(4
9) 
India 
(Karnata
ka) 
Outpatie
nt 
departm
ent of 
tertiary 
hospital 
204 
50% male, 
mean age 70 
years 
Not 
stated 
CVD 
(DM as 
a 
comorbi
dity)  
yes 
cost of 
illness 
(medicines 
only), 
patient 
perspectiv
e 
Case note 
review 
www.cimsasia.com 
(online drug 
information system 
for Asia) 
Direct medical cost -  
Cost of each drug in all 
the prescriptions for 
average cost 
of medications per day. 
Indian 
Rupee 
Shobh
ana 
2000a(
37) 
India 
(Chenna
i) 
One 
private 
hospital 
and one 
free 
Govern
ment 
hospital 
596 (422 
Private 
hospitals
, 174 
Govern
ment 
hospitals
) 
Priv hosp - 
55% male, 
mean age 58 
yrs. Govt hosp 
- 46% male, 
Mean age 55 
yrs. 
01/1998- 
06/1998 DM No 
Cost of 
illness, 
patient 
perspectiv
e 
Patient 
questionnair
e survey 
Self-reported 
Direct Medical costs - 
medicines, lab, doctors 
fee, hospitalisation, 
surgery 
Direct non-medical 
costs - travel 
Indian 
Rupees 
(INR)  
Shobh
ana 
2000b(
38) 
India 
(Chenna
i) 
Speciali
st 
hospital 
270 
Foot comp. 
group - 68% 
male, mean 
age 58 yrs, No 
foot comp. 
group - 50% 
male, mean 
age 55 yrs 
Jan-
June 
1998 
DM 
Type 2 
only 
Yes foot 
complica
tions 
Cost of 
illness 
study, 
patient 
perspectiv
e 
Patient 
interviews Self-reported 
Direct medical costs - 
Doctors fees, specialist 
fees, surgery, 
hospitalisations, lab, 
medicines 
Direct non-medical 
costs - travel, footwear 
Indian 
Rupees 
(INR)  
Shrest
a 
2013(5
5) 
Nepal 
A public 
hospital, 
a private 
hospital 
and two 
poly 
clinics 
227 
Mean age 
49yrs, Male 
59% 
07/2010-
09/2010 DM No 
Cost of 
illness, 
patient 
perspectiv
e 
Patient 
questionnair
e survey 
Self-reported 
Direct Medical Costs - 
doctors fee, lab, 
medicine 
Direct Non-Medical 
Costs - travel, food and 
physical exercise 
Indirect cost - earnings 
US $  
lost due to clinic visit 
and having DM. 
Srivast
ava 
2013(3
3) 
India 
National 
Indian 
surveys 
n/a 
(modelli
ng 
study) 
n/a 
National 
data 
sets - 
2004, 
1995/6, 
2001/3 
CVD 
Not 
specifica
lly 
Macro-
economic 
modelling 
study, 
societal 
perspectiv
e 
Cross-
sectional 
secondary 
data 
analysis 
Self-reported 
(National 
household survey, 
India) 
Direct medical costs - 
admission fee, drugs, 
lab, doctors fee 
Direct non-medical 
costs - travel, "other 
non-medical costs" 
Indian 
Rupees 
(Rs) 
Tharka
r 
2009(4
0) 
India 
diabetes 
specialit
y centre 
( 100 
beds) - 
location 
not 
stated 
443 (269 
without 
hyperten
sion, 
174 with 
hyperten
sion) 
Mean age 55 
yrs, male 53% 
10/2007-
12/2007 
DM (with 
or 
without 
hyperten
sion) 
Only 
hyperten
sion 
Cost of 
illness, 
patient 
perspectiv
e 
Patient 
questionnair
e survey 
Self-reported  
Direct medical costs - 
GRFWRU¶VIHHV
medicines, lab, 
admission, 
investigations, misc. 
Direct non-medical 
costs - misc. (food, 
travel) 
Indian 
Rupees 
(INR)  
Tharka
r 
2010(3
9) 
India 
househo
ld, 
Chennai
, India 
718 
53% male, 
mean age 56 
yrs 
08/2009-
12/2009 
DM with 
or 
without 
complica
tions 
Yes 
Cost of 
illness, 
Societal 
perspectiv
e 
Cross 
sectional 
Household 
survey 
Self-reported 
Direct medical costs - 
hospital service, 
consultation, lab, 
medicine  
Direct non-medical 
costs - food, transport 
Indirect costs - 
productivity losses 
Intangible cost - 
willingness to pay 
Indian 
Rupees 
(INR)  
 
 
Table 3 ± Mean annual costs per patient of cardiovascular disease (CVD), Diabetes Mellitus (DM) and their complications (in US$ 
2015) 
 
Ref. Year Condition Country Quality Score Total costs Direct medical costs 
Direct non-
medical costs Indirect costs Intangible costs 
Cardiovascular Disease 
Karan 
2014 
200
4 CVD 
India 
(national) 78.1%   
 
Mean annual costs -  US$ 563 
 
Mean annual 
costs - US$ 
175.21 
not included not included 
Srivastav
a 2013 
200
4 CVD India 83.8% 
The total cost of hospitalisation for CVDs 
in India in 2004 - US$ 10.2 billion 
 
Modelled estimated costs - 
2010 - US$ 11.7 billion  
2016 - US$ 14.4 billion 
2020 - US$ 16.6 billion  
 
Mean cost of hospitalisation for CVDs per 
person  -  
1995/96 - US$ 1318 
2004 - US$ 1,523 
Not disaggregated not included not included 
Malhotra 
2000 
199
9 
CVD 
(angina - 
unstable) 
India 75.8% Mean total costs per hospitalisation 
episode -  US$ 677 
Mean admission fee : US$ 11 
Cost of prescription per stay: US$ 96; 
Cost of coronary care unit : US$ 145;  
Cost of ward stay: US$ 43;  
Cost of investigation: US$ 154;  
Cost of interventions: US$ 229  
not included not included not included 
Jhaj 
2001 
199
9 
CVD 
(Hyperten
sion) 
India 
(Chandigar
h) 
67.7%   Annual mean drug cost - US$ 79 not included not included not included 
Malhotra 
2001 
200
0 
CVD 
(Hyperten
sion) 
India 51.5% Mean total annual cost - US$ 386 
Mean annual lab costs - US$ 113 
Mean annual drug costs: US$ 231 
Mean annual physician fees: US$ 26 
not included not included not included 
Cardiovascular Disease with Diabetes Mellitus 
Shastry 
2015 
201
4* 
CVD (with 
or without 
DM)  
India 
(Karnataka
) 
50.0% 
Mean cost of prescription per day - 
All medications - US$ 1.14 
Cardiovascular diseases - US$ 0.51 
Diabetic medications - US$ 0.21  
Mean cost of prescription per day - 
All medications - US$ 1.14 
Cardiovascular diseases - US$ 0.51 
Diabetic medications - US$ 0.21 
not included not included not included 
Rao 
2011 
200
4 
CVD and 
DM 
India 
(national) 74.1% 
Average costs per hospitalisation -  
 US$ 1,343 (CVD) and US$ 646 (diabetes) 
Proportion of annual household income - 
30% for CVD and 17% for diabetes  
Not disaggregated from non-medical costs so 
unable to calculate. 
Not disaggregated 
from direct 
medical costs so 
unable to calculate 
not included not included 
Abegund
e 2007 
 
195
0-
200
2** 
CVD and 
DM 
Pakistan, 
India, 
Banglades
h 
83.3% not included not included not included 
Loss of GDP in 
2015 - 
India - US$ 1.96 
billion 
Pakistan - US$ 
0.21 billion 
Bangladesh - 
US$ 0.14 billion 
not included 
Diabetes Mellitus (not specified) 
Shresta 
2013 
201
0 DM Nepal 76.6% 
Mean total cost per outpatient visit -   
US$ 14 
Mean total cost per month - US$ 44 
Mean total cost per year -  
All pts - US$ 483 
Public sector - US$ 219 
Private sector - US$ 606 
Mean cost per visit: - US$ 12 
 
Mean cost per annum -  
All pts - US$ 463 
Public sector - US$ 212 
Private sector - US$ 590 
Mean cost per visit 
- US$ 2.70 
 
Mean annual cost 
- US$ All pts - 
US$21 
Mean cost per 
visit: - US$ 2.24 
 
Mean cost per 
annum -  
Public sector - 
US$ 9 
Private sector - 
US$ 27 
not included 
Akari 
2013 
201
2 DM 
India 
(Andhra 
Pradesh) 
71.0% Without complications - USD 31 With co-morbidities - USD 328  
Without complication - USD 29 
With co-morbidities - USD 303 
Without 
complication - 
USD 0.37 
With co-
morbidities - USD 
3.91 
Without 
complications - 
USD 2.31 
With co-
morbidities - 
USD 21 
not included 
Chandra 
2014 
201
1-12 DM 
India 
(Pune) 45.3%   Average annual cost - US$ 575 
Average annual 
cost - 
US$ 258  
Average annual 
cost - US$ 235 not included 
Kapur 
2007 
199
9** DM India 61.3% Total estimated annual cost: US$ 2,637 Mean total direct cost: - US$ 948 
Not clearly 
presented 
Mean total 
indirect cost: 
US$ 1,689 
not included 
Khowaja 
2007 
200
6 DM 
Pakistan 
(Karachi) 80.6% 
 
Mean annual cost US$ 1,048 Annual mean direct cost US$ 951  
Mean cost for 
travel - US$ 10 
Mean cost for food 
- US$ 2.71 
Mean lost 
productivity of pt 
- US$ 9 
Mean lost 
productivity of 
attendants - US$ 
17 
not included 
Rayappa 
1999 
199
7 DM 
India 
(Bangalore
) 
72.7% 
Total annual costs of diabetes per person - 
Personal - US$ 973 
Family - US$ 1,843 
Society - US$ 2,468 
Average Annual Direct Cost for routine care 
(non-hospitalisation) - US$ 882 
Average Direct Cost per hospitalization - US$ 
1,471 
Average annual cost of lab investigations and 
monitoring - US$ 122 
not included 
Total annual 
indirect cost - 
US$ 2,803 
not included 
Shobhan
a 2000a 
199
8 DM 
India 
(Chennai) 77.9% 
Median total annual expenditure -  
Private hospital patients - US$ 618 
Public hospital patients - US$ 34 
 
Estimated national costs for 20 million DM 
pts could be US$ 12.4billion 
Private hospital patients median spend - 
Medicine - US$ 411 
Lab tests - US$ 49 
Family doctor - US$ 41 
Specialist - US$ 41 
Hospitalisation - US$ 685 
Surgery - US$ 1,233 
 
Public hospital patients median spend - 
Medicine - US4 101 
Lab tests - US$ 33 
Family doctor - US$ 16 
Specialist - US$ 75 
Hospitalisation and surgery - Free care 
Median transport 
costs for private 
hospital patients - 
US$ 33 
 
Median transport 
costs for public 
hospital patients - 
US$ 26 
not included not included 
Diabetes Mellitus type 2 
Ramach
andran 
2007 
200
5 DM type 2  India 65.2% 
Median total expenditure -  
Urban pts - US$ 1,046 
Rural pts -  US$ 655 
Median total expenditure -  
Urban pts - US$ 1,046 
Rural pts -  US$ 655 
not included not included not included 
Adiga 
Sachida
nanda 
2010 
200
8 DM type 2  
India 
(Karnataka
) 
58.1% For hospitalised - US$ 1,216 Annual medicine costs - US$ 648 to 1,963  Annual Consultation costs - US$ 19 to 88 not included not included not included 
Hussain 
2014 
201
3* DM type 2  
Pakistan 
(Karachi) 40.9% 
Average cost - US$ 213 per month (US$ 
2,551 annually) not disaggregated   not disaggregated not included not included 
Kumar 
2008 
200
5 DM type 2  
India 
(Delhi) 73.4%   Average costs ~ US$ 628 per annum. not included not included not included 
Shobhan
a 2000b 
199
8 DM type 2  
India 
(Chennai) 66.1% 
Group without foot complications - US$ 
599 
Group with foot complications - US$ 2,116 
 
Foot complications OP only - US$ 986 
Foot complications IP + OP - US$ 2,316 
Not disaggregated from non-medical costs so 
unable to calculate. 
Group without foot 
complications - 
US$ 38 
Group with foot 
complications - 
US$ 68 
 
Foot complications 
OP only - US$ 58 
Foot complications 
IP + OP - US$ 68 
not included not included 
Diabetes mellitus with complications 
Clarke 
2010 
200
1-
6** 
DM with 
complicati
ons 
India (part 
of multi-
country 
study) 
75.0%   
Major coronary event - US$ 2,087 
Major cerebrovascular event - US$ 2,396 
Heart Failure -  US$ 2,469 
Peripheral vascular - US$ 502 
Nephropathy - US$ 293 
 
History of: 
Major coronary event - US$ 131 
Major cerebrovascular event - US$ 122 
Heart Failure - US$ 205 
Peripheral vascular - US$ 168 
Nephropathy: - US$ 161 
not included not included not included 
Kumpatl
a 2013 
200
8-
200
9** 
DM with 
complicati
ons (type 
2) 
India 69.1% 
Total costs of hospital admission without 
complications - US$ 362 
Total costs of hospital admission with 
complications - US$ 1,024 to 1,534 
 
Estimated 2 year costs (no complications) 
- US$ 2,420 
Estimated 2 year costs (with 
complications) - US$ 8,066 to 22,787 
Not disaggregated from non-medical costs so 
unable to calculate. 
transportation 
charges - US$ 28 
to 81 per 
admission 
not included not included 
Ali 2008 
199
7- 
200
4** 
DM with 
foot ulcers Pakistan 58.8%   
Total Costs - 
Grade 1 foot ulcer = US$ 246 
Grade 2 = US$ 3,406 
Grade 3 = US$ 4,466  
 
Major amputation - US$ 4,204 
Minor amputation -  US$ 4,597  
not included not included not included 
Satyava
ni 2014 
200
8-
201
0** 
DM (type 
2) with or 
without 
CKD 
India 67.2% 
Total expenditure per hospitalisation - 
Transplantation group - US$ 31,694 
Dialysis group - US$ 4,934 
CKD group - US$ 1,020 
No complication group - US$ 259 
 
2 year total expenditure estimate - 
Transplantation group - US$ 27,828 
Dialysis group - US$ 40,331 
CKD group - US$ 8,066 
No complication group - US$ 2,420 
Not disaggregated from non-medical costs so 
unable to calculate. 
The transportation 
charges per 
hospitalisation - 
Transplantation 
group -US$ 262 
Dialysis group - 
US$ 281 
CKD group - US$ 
50 
No complication 
group - US$ 24 
not included not included 
Tharkar 
2010 
200
9 
DM with or 
without 
complicati
ons 
India 89.1% 
Median annual direct cost per patient -US$ 
2,048 
 
Modelled annual national cost of diabetes 
to Indian population (range) - US$ 99.2 
billion to 148.2 billion).  
not disaggregated from non-medical costs so 
unable to calculate. 
Direct non-medical 
cost - 
Per hospitalisation 
- US$ 202 
Per OP 
attendance - US$ 
57 
Median annual 
cost - US$ 401 
Patients' 
willingness to pay 
to stay well -  
Per month - US$ 
161 
Per year - US$ 
1,936 
Tharkar 
2009 
200
7 
DM with or 
without 
hypertensi
on 
India 59.4% 
Mean total expenditure for hospital 
admissions over 2 year period - 
Non-hypertensive group = US$ 2,603 
Hypertensive group = US$ 3,533 
Median total cost for  treatment  of  diabetes  
by  hospitalization  or  inpatient procedure  
was - 
Non-hypertensive group - US$ 1,734 
Hypertensive group - US$ 1,952 
 
Average cost per routine out-patient check up - 
US$ 288 
Food and travel 
costs per 
hospitalisation 
episode - 
Non-hypertensive 
group = US$ 399 
Hypertensive 
group = US$ 470 
not included not included 
Cardiovascular Disease - Stroke 
Khealani 
2003 
199
8-
200
1** 
Stroke Pakistan 66.1%   Total costs per stroke - US$ 8,480 not included not included not included 
Kwatra 
2013 
200
9-
201
1** 
Stroke India 71.9% The mean overall cost at 6 months - US$ 5,966 
Mean direct medical costs - US$ 3,890 
Inpatient care: US$ 2,298 
Outpatient care: US$ 72 
Inpatient rehabilitation: US$ 73 
Outpatient rehabilitation: US$ 470 
Total drugs charges: US$ 1,411 
Mean direct 
nonmedical costs - 
US$ 357 (at 6 
mths) 
Travel cost: US$ 
128 
Other 
expenditures: US$ 
229 
Mean indirect 
costs - US$ 
1,719 (at 6 
mths) 
Patients: US$ 
1,088 
Caregiver: US$ 
631 
not included 
Marfatia 
2014 
201
0-
11** 
Stroke , 
with non-
valvular 
atrial 
fibrillation 
India 86.8% 
Mean total costs per patient during first 12 
months - US$ 32,927 (median US$ 
29,706) 
 
 
Index hospitalization ± US$ 15,366 
Outpatient care - US$ 13,085 
GP visits US$ 3,671 
Rehabilitation services - US$ 2,322 
Laboratory visits - US$ 261 
Imaging visits - US$ 875 
Pharmacotherapy - US$ 5,956 
Nursing home/services - US$ 2,083 
Mean home 
modification costs 
US$ 1,552 
Mean costs for 
informal care 
(days of lost 
productivity) - 
US$ 872 
not included 
* No year of data collection reported, so year is assumed 
** Mid-year used to calculate conversion into 2015 US$ 
  
Table 4  W Summary of annual costs for cardiovascular disease (CVD) and diabetes mellitus (DM) in South Asia (US$ 2015) 
CVD 
Direct medical costs Hypertension outpatient care US$ 386 
Hypertension drugs US$ 79 - 231 
All CVD care per patient US$ 563 
All CVD drugs US$ 415 
CVD Hospitalisation costs  US$ 677 - 1,523 
Per Stroke US$ 3,890 - 28,451 
Direct non-medical costs  Per Stroke US$ 357 - 1,552 
Indirect costs Per Stroke US$ 872  W 1,719 
Loss of (national) productivity due 
to CVD 
India US$ 1.96 billion 
Pakistan US$ 0.21 billion 
Bangladesh US$ 0.14 billion 
Total societal costs Per stroke (First 12 months) US$ 5,966 - 32,927 
DM 
Direct medical costs  Outpatient care US$ 463 - 951 
Including hospitalisation US$ 575 - 1216 
Minor complications US$ 246  W 502 
Major complications US$ 2,087  W 4,597 
Direct non-medical costs Outpatient care US$ 12  W 21 
Including hospitalisation US$ 258 
Complications per admission US$ 50  W 470 
Indirect costs All patients US$ 9 - 2,803 
Intangible costs Willingness to pay to stay well US$ 1,936 
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EconPapers (RePec) 
1. china* or chinese or india or indian or indians or pakistan* or bangladesh* or afghan* or 
maldive* or lanka or nepal* or Bhutan 
2. diabete* or stroke or thrombosis or aneurysm or embolism or dvt or heart or cardiovascular or 
vascular or coronary or angina or myocardial or cardiac 
3. 1 and 2 [in titles and keywords of working papers, articles, books and chapters] 
 
Embase Classic+Embase <1947 to 2015 April 01> 
1     (diabet* or niddm or mody).tw. (641578) 
2     exp *diabetes mellitus/ (388539) 
3     ((heart or cardiovascular or vascular) adj3 disease*).tw. (380855) 
4     ((myocardial or heart*) adj5 infarc*).tw. (219501) 
5     (heart adj6 (disease* or attack*)).tw. (210921) 
6     (coronary adj6 (disease* or syndrome*)).tw. (195411) 
7     (angina or "transient ischaemic attack*").tw. (67311) 
8     (atherosclerosis or arteriosclerosis).tw. (136262) 
9     "peripheral arterial disease".tw. (8682) 
10     (stroke* or (ischemia adj3 brain*) or (infarc* adj3 brain*) or "intercranial haemorrhage*" or 
"intercranial hemorrhage*").tw. (250823) 
11     (thrombosis or occulsion* or thromboses or aneurysm* or embolism*).tw. (321198) 
12     DVT.tw. (11938) 
13     ("atheromatous plaque" or atheromata*).tw. (1581) 
 14     *heart disease/ or *cardiovascular disease/ or *heart failure/ or exp *heart arrest/ (218801) 
15     *vascular disease/ or exp *peripheral vascular disease/ or exp *portal hypertension/ or exp 
*thromboembolism/ (970367) 
16     *ischemic colitis/ (1405) 
17     exp *ischemic heart disease/ or *heart muscle ischemia/ (293815) 
18     exp *cardiomegaly/ (23258) 
19     exp *diabetic angiopathy/ (6269) 
20     exp *artery occlusion/ (42515) 
21     *prehypertension/ or *hypertension/ (193494) 
22     *reperfusion injury/ (21122) 
23     exp *retina vein occlusion/ (3792) 
24     *cerebrovascular accident/ (47933) 
25     or/1-24 [Diabetes or CVD terms] (2569474) 
26     China/ (110932) 
27     India/ (101303) 
28     Pakistan/ (17294) 
29     Bangladesh/ (10228) 
30     Afghanistan/ (3940) 
31     nepal/ (6798) 
32     Sri Lanka/ (5814) 
33     Bhutan/ (365) 
34     maldives/ (143) 
35     (china or chinese or india or indian or pakistan* or bangladesh*).ti,ab,in. (1826291) 
36     (afghanistan* or maldives or bhutan* or nepal* or "sri lanka*").ti,ab,in. (25293) 
37     or/26-36 [SE Asian World Bank LMICs] (1886276) 
38     *budget/ (4899) 
 39     budget impact stud*.tw. (9) 
40     (cost* or economic* or expenditure*).ti. (161426) 
41     "cost of illness"/ (14986) 
42     exp *economic evaluation/ (38228) 
43     (expenditure* adj5 (healthcare or medical or treatment)).tw. (5796) 
44     (economic* adj2 (analysis or burden or evaluation* or consequence*)).ab. (21004) 
45     (cost* adj2 (illness or evaluat* or analy* or compar* or efficienc* or estimate*)).ab. (54565) 
46     or/38-45 (216687) 
47     25 and 37 and 46 (1123) 
48     exp animals/ not (exp animals/ and exp humans/) (4681580) 
49     exp nonhuman/ not (exp nonhuman/ and exp human/) (3548685) 
50     exp experimental animal/ (465642) 
51     exp veterinary medicine/ (34563) 
52     animal experiment/ (1843743) 
53     ((energy or oxygen* or metaboli*) adj3 (expenditure* or cost*)).tw. (29818) 
54     or/48-53 (6293730) 
55     47 not 54 (1035) 
 
Global Health <1973 to 2015 Week 12> 
1     (diabet* or niddm or mody).tw. (84109) 
2     diabetes/ or diabetes mellitus/ (50886) 
3     exp cardiovascular diseases/ (78197) 
4     ((heart or cardiovascular or vascular) adj3 disease*).tw. (75247) 
5     ((myocardial or heart*) adj5 infarc*).tw. (8505) 
6     (heart adj6 (disease* or attack*)).tw. (40986) 
7     (coronary adj6 (disease* or syndrome*)).tw. (31595) 
 8     (angina or "transient ischaemic attack*").tw. (1975) 
9     (atherosclerosis or arteriosclerosis).tw. (16605) 
10     "peripheral arterial disease".tw. (510) 
11     (stroke* or (ischemia adj3 brain*) or (infarc* adj3 brain*) or "intercranial haemorrhage*" or 
"intercranial hemorrhage*").tw. (12558) 
12     (thrombosis or occulsion* or thromboses or aneurysm* or embolism*).tw. (7506) 
13     DVT.tw. (262) 
14     ("atheromatous plaque" or atheromata*).tw. (99) 
15     or/1-14 [CVD or Diabetes] (170221) 
16     (china or chinese or india or indian or pakistan* or bangladesh*).ti,ab,in. (387962) 
17     (afghanistan* or maldives or bhutan* or nepal* or "sri lanka*").ti,ab,in. (10166) 
18     exp bangladesh/ (7253) 
19     exp India/ (72195) 
20     exp china/ (109156) 
21     exp Pakistan/ (9714) 
22     afghanistan/ (1121) 
23     maldives/ (88) 
24     bhutan/ (227) 
25     nepal/ (3979) 
26     sri lanka/ (3152) 
27     or/16-26 [SE Asian World Bank LMICs] (405865) 
28     economic evaluation/ (526) 
29     health care costs/ (7166) 
30     budgets/ (233) 
31     budget impact stud*.tw. (1) 
32     (cost* or economic* or expenditure*).ti. (23122) 
 33     (cost* adj2 (illness or evaluat* or analy* or compar* or efficienc* or estimate*)).ab. (7533) 
34     (economic* adj2 (analysis or burden or evaluation* or consequence*)).ab. (3480) 
35     (expenditure* adj5 (healthcare or medical or treatment)).ab. (945) 
36     or/28-35 [Cost Studies] (31990) 
37     15 and 27 and 36 (267) 
38     exp animals/ not (man/ or women/) (524796) 
39     ((energy or oxygen* or metaboli*) adj3 (expenditure* or cost*)).tw. (10100) 
40     38 or 39 (533179) 
41     37 not 40 (233) 
 
Ovid MEDLINE(R) <1946 to March Week 5 2015> 
1     exp Diabetes Mellitus/ (322574) 
2     (diabet* or niddm or mody).tw. (397491) 
3     ((heart or cardiovascular or vascular) adj3 disease*).tw. (247187) 
4     cardiovascular diseases/ or heart diseases/ or cardiac output, high/ or cardiac output, low/ or 
cardiomegaly/ or heart aneurysm/ or heart arrest/ or heart failure/ or myocardial ischemia/ or vascular 
diseases/ or arterial occlusive diseases/ or cerebrovascular disorders/ or colitis, ischemic/ or diabetic 
angiopathies/ or "embolism and thrombosis"/ or hypertension/ or optic neuropathy, ischemic/ or 
peripheral vascular diseases/ or prehypertension/ or reperfusion injury/ or retinal vein occlusion/ 
(622120) 
5     ((myocardial or heart*) adj5 infarc*).tw. (145464) 
6     (heart adj6 (disease* or attack*)).tw. (137474) 
7     (coronary adj6 (disease* or syndrome*)).tw. (126119) 
8     (angina or "transient ischaemic attack*").tw. (44698) 
9     exp Atherosclerosis/ (23981) 
10     (atherosclerosis or arteriosclerosis).tw. (88321) 
11     "peripheral arterial disease".tw. (5429) 
 12     (stroke* or (ischemia adj3 brain*) or (infarc* adj3 brain*) or "intercranial haemorrhage*" or 
"intercranial hemorrhage*").tw. (153299) 
13     thrombosis/ or coronary thrombosis/ or exp thromboembolism/ or exp venous thrombosis/ 
(144247) 
14     (thrombosis or occulsion* or thromboses or aneurysm* or embolism*).tw. (207687) 
15     DVT.tw. (6302) 
16     ("atheromatous plaque" or atheromata*).tw. (1018) 
17     Stroke/ (62926) 
18     or/1-17 [Diabetes or CVD] (1648865) 
19     exp china/ or bangladesh/ or exp india/ or pakistan/ (194127) 
20     (china or chinese or india or indian or pakistan* or bangladesh*).ti,ab,in. (910571) 
21     (afghanistan* or maldives or bhutan* or nepal* or "sri lanka*").ti,ab,in. (15461) 
22     afghanistan/ (2341) 
23     Nepal/ (5096) 
24     Sri Lanka/ (4203) 
25     Bhutan/ (211) 
26     or/19-25 [SE Asian World Bank LMIC Countries] (968791) 
27     exp "Costs and Cost Analysis"/ (185787) 
28     exp budgets/ (12272) 
29     budget impact stud*.tw. (4) 
30     (cost* or economic* or expenditure*).ti. (113918) 
31     (cost* adj2 (illness or evaluat* or analy* or compar* or efficienc* or estimate*)).ab. (33530) 
32     (economic* adj2 (analysis or burden or evaluation* or consequence*)).ab. (12628) 
33     (expenditure* adj5 (healthcare or medical or treatment)).ab. (3644) 
34     or/27-33 [Cost Studies] (255440) 
35     18 and 26 and 34 (592) 
 36     exp animals/ not (exp animals/ and exp humans/) (4003797) 
37     exp Veterinary Medicine/ (21693) 
38     exp Animal Experimentation/ (6539) 
39     ((energy or oxygen* or metaboli*) adj3 (expenditure* or cost*)).tw. (21844) 
40     or/36-39 (4036443) 
41     35 not 40 [CVD Diabetes Costs and Countries] (558) 
 
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations <April 01, 2015> 
 
1     (diabet* or niddm or mody).tw. (36485) 
2     ((heart or cardiovascular or vascular) adj3 disease*).tw. (20289) 
3     ((myocardial or heart*) adj5 infarc*).tw. (8129) 
4     (heart adj6 (disease* or attack*)).tw. (9106) 
5     (coronary adj6 (disease* or syndrome*)).tw. (8857) 
6     (angina or "transient ischaemic attack*").tw. (2064) 
7     (atherosclerosis or arteriosclerosis).tw. (5830) 
8     "peripheral arterial disease".tw. (495) 
9     (stroke* or (ischemia adj3 brain*) or (infarc* adj3 brain*) or "intercranial haemorrhage*" or 
"intercranial hemorrhage*").tw. (15126) 
10     (thrombosis or occulsion* or thromboses or aneurysm* or embolism*).tw. (14982) 
11     DVT.tw. (610) 
12     ("atheromatous plaque" or atheromata*).tw. (49) 
13     budget impact stud*.tw. (2) 
14     (cost* or economic* or expenditure*).ti. (10353) 
15     (cost* adj2 (illness illness or evaluat* or analy* or compar* or efficienc* or estimate*)).ab. (3765) 
16     (economic* adj2 (analysis or burden or evaluation* or consequence*)).ab. (1911) 
 17     (expenditure* adj5 (healthcare or medical or treatment)).ab. (443) 
18     or/13-17 [Cost Studies] (13343) 
19     (china or chinese or india or indian or pakistan* or bangladesh*).ti,ab,in. (249078) 
20     (afghanistan* or maldives or bhutan* or nepal* or "sri lanka*").ti,ab,in. (2578) 
21     19 or 20 [SE Asian World Bank LMICs] (251129) 
22     or/1-12 [CVD or Diabetes] (89343) 
23     18 and 21 and 22 (93) 
 
NHS Economic Evaluation Database : Issue 1 of 4, January 2015 (Wiley) 
#1 (diabet* or niddm or mody):ti,ab  
#2 ((heart or cardiovascular or vascular) near/3 disease*):ti,ab  
#3 ((myocardial or heart*) near/5 infarc*):ti,ab  
#4 (heart near/6 (disease* or attack*)):ti,ab  
#5 (coronary near/6 (disease* or syndrome*)):ti,ab  
#6 (angina or "transient ischaemic attack*"):ti,ab  
#7 (atherosclerosis or arteriosclerosis):ti,ab  
#8 "peripheral arterial disease":ti,ab  
#9 (stroke* or (ischemia near/3 brain*) or (infarc* near/3 brain*) or "intercranial haemorrhage*" 
or "intercranial hemorrhage*"):ti,ab  
#10 (thrombosis or occulsion* or thromboses or aneurysm* or embolism*):ti,ab  
#11 DVT:ti,ab  
#12 ("atheromatous plaque" or atheromata*):ti,ab  
#13 MeSH descriptor: [Diabetes Mellitus] explode all trees 
#14 MeSH descriptor: [Cardiovascular Diseases] explode all trees 
#15 MeSH descriptor: [Stroke] explode all trees 
#16 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15  
 #17 MeSH descriptor: [China] explode all trees 
#18 MeSH descriptor: [India] explode all trees 
#19 MeSH descriptor: [Pakistan] explode all trees 
#20 MeSH descriptor: [Bangladesh] explode all trees 
#21 MeSH descriptor: [Afghanistan] this term only 
#22 MeSH descriptor: [Sri Lanka] this term only 
#23 MeSH descriptor: [Nepal] this term only 
#24 MeSH descriptor: [Bhutan] this term only 
#25 (china or Chinese or india or indian or Indians or Pakistan* or Bangladesh*):ti,ab  
#26 (afghan* or Bhutan or Maldives or "sri lanka" or Nepal*):ti,ab  
#27 #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26  
#28 #16 and #27  
 
WHOLIS  World Heatlh Organization Library & Information Networks for 
Knowledge Database 
 
^ĞĂƌĐŚĞƐŝŶ ‘ǁŽƌĚƐĂŶĚƉŚƌĂƐĞƐ ? 
 
1. diabetes or diabetic or heart or cardiac or stroke or thrombosis or aneurysm or embolism or dvt 
or cardiovascular or vascular or coronary or angina or myocardial 
2. cost or economic or expediture or budget 
3. india or indians or china or chinese or pakistan or pakistani or bangladesh or Bangladeshi or 
nepal or nepalese or bhutan or maldives or afghanistan or afghanistani or lanka 
4. 1 and 2 and 3 
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Reviewer:  
Date of Review 
 
Authors:  
 
Title  
Reference:  
 
Year:   
Country:  
 
Language  
Meeting exclusion 
criteria  
Give yes/no answer, if 
yes give details about 
which exclusion criteria is 
met:  
Yes/ No  
Exclusion criteria  
- no full text publication was available, and Conference abstracts 
only available 
- Written in language other than English, Chinese, Hindi, Urdu 
or  Bengali 
- Costs not relating to costs of usual care in the setting at the time, 
or only to costs of an intervention 
Aim of study:  
Condition  
What condition does the 
study address and how 
was it defined? 
 
Patient population    
Setting:   
Year of data collection  
Sample Size  
Recruitment process  
Exclusion criteria:  
Population 
demographics assessed 
 
Economic study design  
Study Type 
Is the study type clearly 
specified, what study type 
is it reported as, and is 
 
 this consistent with the 
methodology presented 
Perspective of the 
analysis: 
1) patient only; 2) societal 3) 
health service 
 
The Analysis process used 
how was the data analysis 
performed? Including 
projections or only 
timeframe of data 
collection?  
 
Economic Modelling:  
Was modelling performed? 
if yes, what models were 
used (description) and what 
information informed the 
model?  
 
Source of cost data:  
Primary outcome 
measures(if applicable) 
What measures were used? 
 
Costs included 
(including sources)  
 
 Direct medical costs 
This includes all 
expenditures relating to 
medical care (Hospital 
admissions, 
Investigations, treatment 
(including medication), 
out-patient visits etc.)  
 
Direct non-medical 
costs: 
This includes all 
expenditure incurred as a 
result of the disease or 
condition that are not 
medical expenditures 
(travel costs, subsistence 
costs, accommodation 
costs, costs for support or 
 
 changes to home 
environment etc.) 
Indirect costs: 
Indirect cost are not direct 
expenditures, but costs 
incurred as a result of the 
illness (like time off 
work, loss of income, 
opportunity cost, 
Sickness, disability, 
premature retirement or 
premature mortality etc) 
 
Intangible costs:  
By definition, intangible 
costs are costs that are 
difficult to capture. This 
includes cost to society, 
like absteentism, pain, 
anxiety, inconvenience, 
loss of quality of life etc) 
 
Excluded costs: 
Give information as to costs 
that are clearly mentioned 
as excluded, or that you can 
see that have not been 
included 
 
Source of resource use 
and unit costs: 
 
Currency:  
Price year:  
Also include what methods 
were used for conversion of 
prices if relevant. 
 
Discounting 
(costs/benefits) 
( Was discounting done I 
time horizon of the study 
> 1year, and if yes what 
rate was applied and were 
they applied to costs and / 
or benefits): 
 
Sensitivity analysis: 
(was a sensitivity analysis 
performed, was 
parameters were 
 
 modelled, and did what 
was the outcome of it?) 
Cost results 
 
Direct Medical: . 
Direct non-medical:  
Indirect   
Intangible  
Cost for patient  
Cost for health care 
service 
 
Costs for society:  
Other costs:  
$XWKRUV¶FRQFOXVLRQV 
 
 
Summary Findings: 
 
 
 
Comments ± limitations:   
 
Quality Checklist : 
       
Item yes no partial not clear NA comment 
study question stated and well defined? 
  
 
   
well defined aim of the study? 
  
 
   
Is the study population described ? 
  
 
   
Is the study population representative of 
the source population?  
      
Is the process of identifying and recruiting 
subjects clear and appropriate?  
      
Is the study setting and location clearly 
defined? 
  
 
   
Was the disease adequately defined? 
  
 
   
Has the study perspective been clearly 
defined? 
  
 
   
Is the time horizon clearly specified? 
  
 
   
The form of economic evaluation used is 
stated 
  
 
   
The choice of form of economic evaluation 
is justified in relation to the questions 
addressed. 
  
 
   
 Was an appropriate method of 
quantification used? 
  
 
   
Was the resource quantification well 
executed? 
  
 
   
MEASUREMENT OF RESOURCES DATA       
Are the sources used to collect resource 
utilisation data reported clearly (e.g. clinical 
trials, administrative databases, clinical 
databases, medical records and published 
literature)? 
  
 
   
Are the resource quantities reported 
independently from the costs, so that 
assessment of the measurement method is 
facilitated? 
 
 
    
Are any assumptions in the measurement of 
resources explicitly reported and justified? 
 
 
    
If an expert was consulted to estimate some 
of the resources, are the methods used 
described? 
    
 
 
If this is a trial: were the resource estimates 
collected prospectively alongside 
effectiveness data, utilising the robust 
infrastructure established for the trial? 
    
 
 
If the resources utilised were identified 
through a literature review are details of the 
review process provided and robust? 
    
 
 
VALUATION  OF RESOURCES DATA       
Are all the sources used to obtain unit costs 
reported and relevant for the specific study 
setting? 
 
 
    
If prices were used instead of costs and 
cost-to-charge ratios calculated, do these 
reflect the true opportunity costs of the 
strategies compared? 
    
 
 
Did the analysis address the study question? 
  
 
   
Was a range of estimates presented? 
  
 
   
Were the main uncertainties identified? 
  
 
   
Was a sensitivity analysis performed? (and 
variables varied justified) 
  
 
   
Discount rate is stated and justified?  
(If the time horizon for estimating costs was 
longer than one year was discounting 
performed in order to reflect time 
preferences?) 
  
 
   
Reports currency, price date and 
conversion?  
  
 
   
 Are all costs adjusted to a specific price year 
so that the effects of inflation are removed 
from the cost estimation? 
      
Details of model used given? 
  
 
   
Was adequate documentation and 
justification given for cost components, data 
sources, assumptions and methods? 
  
 
   
Were all included costs clearly described 
and all relevant costs included?  
      
Were the costs addressed related to usual 
practice in that country/ setting? 
      
Was uncertainty around estimations and its 
implications as well as limitations, 
discussed? 
  
 
   
Were the results presented at the 
appropriate level of detail to answer the 
study question?  
  
 
   
Is the answer to the study question given? 
  
 
   
Conclusion follow from the data reported? 
  
 
   
Are the study results internally valid (i.e 
unbiased)? How well did study minimise 
bias? Any significant flaws in study design?  
  
 
   
Are the findings generalizable to the source 
population (i.e externally valid)? Sufficient 
details given to determine if findings 
generalizable to source population? 
      
summary score        
Score 
   
   
If yes is >70% good quality  
If yes is >50% fair quality  
If yes is <49% then weak quality 
 
 
